Aeglea BioTherapeutics to Participate in the Needham Virtual Healthcare Conferences in April 2022
Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE) announced its participation in the 21st Annual Needham Virtual Healthcare Conference, taking place from April 11-14, 2022. Aeglea's president and CEO, Anthony G. Quinn, will present on April 13 at 9:30 a.m. EDT. The company focuses on human enzyme therapeutics for rare metabolic diseases, having recently reported positive data from its PEACE Phase 3 clinical trial for pegzilarginase, designed for Arginase 1 Deficiency. Aeglea also has an active trial for AGLE-177 targeting Homocystinuria. For more details, visit their website.
- None.
- None.
AUSTIN, Texas, April 6, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its participation in two investor conferences as follows:
Conference: 21st Annual Needham Virtual Healthcare Conference, April 11-14, 2022
Presentation Date/Time: Wednesday, April 13 at 9:30 a.m. EDT
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea's president and CEO
Webcast: https://wsw.com/webcast/needham117/agle/2213747
To access live and/or archived Investor Conference webcasts, visit the Events & Presentations section of the Company's website. A replay of Company webcasts is archived on the website for 30 days following presentations.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. In December 2021, Aeglea announced positive topline data from its PEACE Phase 3 clinical trial for its lead product candidate, pegzilarginase, in patients with Arginase 1 Deficiency. Pegzilarginase has received both Rare Pediatric Disease and Breakthrough Therapy Designations. Aeglea also has an ongoing Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families. For more information, please visit http://aeglea.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-to-participate-in-the-needham-virtual-healthcare-conferences-in-april-2022-301518753.html
SOURCE Aeglea BioTherapeutics, Inc.
FAQ
What is Aeglea BioTherapeutics participating in April 2022?
When will Aeglea present at the Needham Conference?
Who is presenting for Aeglea BioTherapeutics at the conference?
What is AGLE's recent clinical trial achievement?
What designations has pegzilarginase received?
What is the purpose of AGLE-177?
